RA Cap­i­tal-backed cell ther­a­py play­er in the neoanti­gen game grabs a $121M megaround to fund first hu­man stud­ies

There’s more than 1 way to skin a mouse. And any­one who fig­ures out the best way in on­col­o­gy can open the door to a valu­able new plat­form tech­nol­o­gy.

Un­daunt­ed by the pi­o­neers who have gone ahead in per­son­al­ized neoanti­gen R&D work, the team at Achilles Ther­a­peu­tics op­er­at­ing out of Steve­nage in the UK be­lieve they have found a bet­ter ther­a­peu­tic ap­proach  — start­ing with non-small cell lung can­cer and in melanoma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.